Teacher Retirement System of Texas Boosts Stake in Edwards Lifesciences Corporation $EW

Teacher Retirement System of Texas grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 90.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 200,964 shares of the medical research company’s stock after buying an additional 95,606 shares during the period. Teacher Retirement System of Texas’ holdings in Edwards Lifesciences were worth $15,717,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences in the second quarter worth $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences in the first quarter worth $27,000. Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $29,000. Finally, Costello Asset Management INC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $29,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Up 1.8%

EW opened at $82.26 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a fifty day moving average of $77.49 and a two-hundred day moving average of $76.65. The stock has a market capitalization of $48.29 billion, a price-to-earnings ratio of 11.84, a PEG ratio of 3.88 and a beta of 1.05.

Analysts Set New Price Targets

EW has been the subject of several recent research reports. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.